Current Edition


Khondrion Presents Phase II KHENERGY Trial Data

Khondrion, a leading clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, today announced results from its KHENERGY study, a Phase II exploratory …

Continue Reading →

First Ever Effective Intervention Against Dementia Shown in Large Study

Researchers just published the first randomized controlled trial ever to show an intervention effective at lowering the risk of dementia.  A computerized brain exercise licensed …

Continue Reading →